Richard Ascroft, the company's chief executive officer for the North America business, stated that the Mumbai-based drug maker already has a manufacturing footprint in the US. (Photo: Company website) Show Quick Read Summary is AI Generated. Newsroom Reviewed

Drug major Sun Pharmaceutical Industries Ltd. on Wednesday said it is open to enhancing its manufacturing footprint in the US amid the Trump administration imposing a 100% tariff on branded and patented medicines.

In an analyst call, Richard Ascroft, the company's chief executive officer for the North America business, stated that the Mumbai-based drug maker already has a manufacturing footprint in the US.

"We are kind of constantly assessing that manufacturing footprint, and we are open to considering this in the US in due ti

See Full Page